Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and AndexXa™ (andexanet alfa) at International ...
23 Mai 2016 - 2:00PM
Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) today announced that
the full data set from the Phase 3 APEX Study of betrixaban will be
featured in an oral session at the 62nd Annual Scientific and
Standardization Committee (SSC) Meeting of the International
Society on Thrombosis and Haemostasis (ISTH), which will take
place from May 25-28 in Montpellier, France.
Additionally, new data from pharmacokinetic and mechanism of action
studies of the Company’s Factor Xa inhibitor antidote AndexXaTM
(andexanet alfa) will be presented in poster sessions.
Portola will host an investor event, which will be
webcast, on Friday, May 27, at 5:00 p.m. CEST following the APEX
data presentation at the ISTH SSC Meeting. Members of Portola’s
senior management team and Dr. C. Michael Gibson, member of the
APEX Executive Committee, and Dr. Alexander (Ander) T. Cohen,
co-principal investigator of the APEX Study, will present and
discuss the full APEX Study results.
The abstracts are now available at
https://www.isth.org/mpage/2016ProgramGlance. Following are details
of the presentations, which will include additional data not
available in the posted abstracts.
Betrixaban Oral Presentation
Details
- Abstract Title (abstract #242): VTE prevention
in acutely ill medical patients with extended duration betrixaban –
a multicenter, randomized, active-controlled efficacy and safety
study comparing extended duration betrixaban with standard of care
enoxaparinPresenting Author: C. Michael
Gibson, M.S., M.D., professor of medicine, Harvard Medical
School, PERFUSE Study Group, Beth Israel Deaconess Medical
CenterSession Title: Control of Anticoagulation,
Part 1Presentation Date and Time: Friday, May
27, 2:30 p.m. CESTLocation: Le Corum
Conference Centre, Einstein Room
AndexXa (andexanet alfa) Poster
Presentation Details
- Abstract Title (abstract #CA08): The effect of
andexanet alfa on the pharmacokinetics and renal clearance of the
direct Factor Xa inhibitors apixaban, rivaroxaban, edoxaban and
betrixabanPresenting Author: Janet M. Leeds,
Ph.D., Senior Director, Drug Metabolism and Pharmacokinetics,
Portola PharmaceuticalsSession Title: Poster
Session and NetworkingPresentation Date and
Time: Wednesday, May 25, 7:00-9:00 p.m.
CEST Location: Le Corum Conference
Centre, Joffre 1-3
- Abstract Title (abstract #CA53): Comparing
mechanisms of action of novel anticoagulant reversal agents through
studies on binding partners and on clot formation and clot
structure Presenting Author: Charles Haynes,
Ph.D., professor at the University of British Columbia, Centre for
Blood Research and Michael Smith Labs, VancouverSession
Title: Poster Session and NetworkingPresentation
Date and Time: Wednesday, May 25, 7:00-9:00 p.m.
CEST Location: Le Corum Conference
Centre, Joffre 1-3
Investor Event Webcast
InformationThe investor event will take place from
5:00-6:00 p.m. CEST/11 a.m.-12 p.m. EDT on May 27 and will be
simultaneously webcast. To access the live and subsequently
archived webcast, go to the Investor Relations section of the
company's website at http://investors.portola.com. A replay will be
available for 30 days following the live event.
About BetrixabanPortola is
developing betrixaban, an oral Factor Xa inhibitor anticoagulant,
for the prevention of venous thromboembolism (VTE), or blood clots,
in acute medically ill patients. Betrixaban directly inhibits the
activity of Factor Xa, an important validated target in the blood
coagulation pathway, to prevent life-threatening thrombosis.
The Phase 3 APEX (Acute Medically Ill VTE
Prevention with Extended Duration Betrixaban) Study evaluated the
superiority of extended-duration anticoagulation with oral
betrixaban compared with standard of care anticoagulation with
injectable enoxaparin for the prevention of VTE in acute medically
ill patients. APEX enrolled 7,513 patients at more than 450
clinical sites worldwide. Portola announced topline
data from the APEX Study on March 24, 2016.
About AndexXa (andexanet
alfa)Portola is developing AndexXa, a U.S. Food and Drug
Administration (FDA)-designated Breakthrough Therapy, for patients
treated with a direct or indirect Factor Xa inhibitor when reversal
of anticoagulation is needed, such as for life-threatening or
uncontrolled bleeding or emergency surgery and urgent
procedures.
AndexXa, an investigational drug, is a modified
human Factor Xa molecule that acts as a decoy to target and
sequester with high specificity both oral and injectable Factor Xa
inhibitors in the blood. Once bound, the Factor Xa inhibitors are
unable to bind to and inhibit native Factor Xa, thus allowing for
the restoration of normal hemostatic processes. AndexXa is the only
compound being studied as an antidote for Factor Xa inhibitors that
directly and specifically corrects anti-Factor Xa activity – the
anticoagulant mechanism of these agents.
About Portola Pharmaceuticals,
Inc. Portola Pharmaceuticals is a biopharmaceutical
company developing product candidates that could significantly
advance the fields of thrombosis and other hematologic diseases.
The Company is advancing three programs, including betrixaban, an
oral, once-daily Factor Xa inhibitor; AndexXa (andexanet alfa), a
recombinant protein designed to reverse the anticoagulant effect in
patients treated with an oral or injectable Factor Xa inhibitor;
and cerdulatinib, a Syk/JAK inhibitor in development to treat
hematologic cancers. Portola's partnered program is focused on
developing selective Syk inhibitors for inflammatory conditions.
For more information, visit www.portola.com and follow the
Company on Twitter @Portola_Pharma.
Investor Contact:
Ana Kapor
Portola Pharmaceuticals
ir@portola.com
Media Contact:
Julie Normart
W2O Group
jnormart@w2ogroup.com
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024